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To assess the current incidence, clinical features, risk factors, aetiology, antimicrobial resis-
tance and outcomes of polymicrobial bloodstream infection (PBSI) in patients with cancer.
Methods
All prospectively collected episodes of PBSI in hospitalised patients were compared with
episodes of monomicrobial bloodstream infection (MBSI) between 2006 and 2015.
Results
We identified 194 (10.2%) episodes of PBSI and 1702 MBSI (89.8%). The presence of cho-
langitis, biliary stenting, neutropenia, corticosteroids, neutropenic enterocolitis and other
abdominal infections were identified as risk factors for PBSI. Overall, Gram-negative organ-
isms were the most frequent aetiology, but Enterococcus spp. were especially frequent
causes of Gram-positive PBSI (30.8%). Multidrug-resistant (MDR) organisms were more
commonly found in PBSI than in MBSI (20.6% vs 12.9%; p = 0.003). Compared to patients
with MBSI, those with PBSI presented with higher early (15% vs 1.4%; p = 0.04) and overall
(32% vs 20.9%; p<0.001) case-fatality rates. Risk factors for overall case-fatality were a
high-risk MASCC (Multinational Association of Supportive Care in Cancer) index score, cor-
ticosteroid use, persistent bacteraemia and septic shock.
Conclusions
PBSI is a frequent complication in patients with cancer and is responsible for high mortality
rates. Physicians should identify patients at risk for PBSI and provide empiric antibiotic therapy
that covers the most frequent pathogens involved in these infections, including MDR strains.
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Introduction
Bloodstream infection (BSI) is a frequent complication in patients with cancer and results in
important levels of morbidity and mortality [1]. Changes in the epidemiology of BSI have
recently been documented in patients with cancer, showing a swift towards Gram-negative
organisms as the leading cause of BSI in some institutions [2–4]. Also, infections due to MDR
bacteria is an emerging problem in immunosuppressed patients with cancer, who are at higher
for severe sepsis and poor outcomes than their immunocompromised peers [4–6].
Patients with cancer and chemotherapy-induced neutropenia, gastrointestinal mucositis,
and medical devices in situ are at increased risk of BSI [7]. In this setting, BSI may be
caused by multiple organisms in which the clinical presentation, microbiology and out-
comes can vary from those caused by only one pathogen. The existing literature regarding
such polymicrobial BSI (PBSI) is very limited, and mainly comprises old retrospective stud-
ies in the general population [8–12]. Few reports have specifically focused on patients with
cancer [13–15]. Moreover, the lack of consistent PBSI definitions and the heterogeneity of
populations in the previous studies makes it very difficult to understand the true relevance
of PBSI [14].
In the recent years, changes in the general management of patients with cancer have
occurred, including the introduction of newer types of myeloablative chemotherapies, trans-
plants, and immunosuppressive agents, and changes in antibacterial and antifungal prophy-
laxis. These innovations may have influenced the frequency and characteristics of PBSI in
patients with cancer.
The aim of this study was to explore the current incidence, clinical features, risk factors,
aetiology, antimicrobial resistance and outcomes of PBSI in patients with cancer during the
present era of widespread antimicrobial resistance.
Materials and methods
Setting, patients and study design
We conducted a prospective observational study at a 200-bed university referral centre for
adults with cancer in Barcelona, Spain. We analysed all consecutive episodes of PBSI occurring
in patients with cancer, including haematopoietic stem cell transplant recipients, from January
2006 to December 2015. Information on baseline characteristics, clinical features, aetiology,
empirical antibiotic therapy and outcome were prospectively collected in a database, as part of
the standard infectious disease management at our hospital. We also compared the character-
istics of patients who died with those who survived to determine the factors influencing mor-
tality. The study was approved by The Clinical Research Ethics Committee and Institutional
Review Board of Hospital Universitari de Bellvitge.
Definitions
PBSI was defined as present if two or more organisms were isolated from blood culture speci-
mens collected from a patient during a period of<72h [13]. Chronic advanced cancer was
considered in patients with confirmed metastatic disease (stage IV) and some stage III
tumours (lung, pancreas, gastric, oesophagus, and urothelium) that were not suitable for treat-
ment or were in progressive outbreak during treatment. Breast and prostate cancer with bone
metastasis, colorectal cancer with resectable hepatic and lung metastasis, and metastatic germi-
nal tumours were excluded.
BSI was considered nosocomial-acquired, healthcare-related or community-acquired, as pre-
viously described [16]. Neutropenia was defined as an absolute neutrophil count<500/mm3.
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Corticosteroid therapy was recorded if a patient was receiving corticosteroids at the time of BSI
or at any point in the previous month. Shock was defined as a systolic blood pressure<90
mmHg that was unresponsive to fluid treatment or that required vasoactive drug therapy. Neu-
tropenic enterocolitis was defined as the presence of fever, abdominal pain, and diarrhoea with
imaging (ultrasonography, CT scanning) confirming the diagnosis [17]. The BSI was consid-
ered endogenous if no other sources were identified in neutropenic patient.
Initial empirical antibiotic therapy was considered inadequate if the treatment regimen did
not include at least one antibiotic active in vitro against the infecting microorganism. Gram-
negative bacilli were considered multidrug-resistant (MDR) if any of the following were pres-
ent: a) extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae; b) AmpC-
cephalosporinase hyper-producing Enterobacteriaceae; c) carbapenem-resistant Enterobacter-
iaceae; d) microorganisms with intrinsic resistance mechanisms, such as Stenotrophomonas
maltophilia; and e) MDR strains, including Pseudomonas aeruginosa and Acinetobacter bau-
mannii [18].
The early case-fatality rate was defined as death within 7 days of the onset of BSI. The over-
all case-fatality rate was defined as death from any cause within the first 30 days of onset of
BSI.
Microbiologic studies
Two sets of two 8–10 mL blood samples (BactecPlus Aerobic and Anaerobic, BD) were taken
30 min apart from all patients who presented with fever38˚C or when BSI was suspected
based on clinical signs or symptoms. Blood samples were processed in a BACTEC 9240 (from
the year 2006 to May 2010) or a BACTEC-FX (since May 2010) apparatus (BD Microbiology
Systems) with an incubation period of 5 days. Positive blood samples were sub-cultured onto
chocolate agar.
Identification and antibiotic susceptibility testing of Gram-negative bacilli, Enterococcus
spp. and Staphylococcus aureus was performed using commercially available panels (Micro-
Scan Beckman-Coulter). Identification of other Streptococcus spp. was performed by standard
biochemical testing and antibiotic susceptibility with commercially available panels (Sensititre,
TREK Diagnostic System). Anaerobe identification was performed by standard biochemical
testing and antibiotic susceptibility by the E-test method (BioMérieux). In addition, identifica-
tion has been performed by matrix-assisted laser desorption/ionisation(MALDI-TOF; Bioty-
per; Bruker Daltonics) since November 2012.The recommendations and criteria of the
Clinical and Laboratory Standards Institute (CLSI) were used to define the susceptibility or
resistance to antimicrobial agents [19]
Statistical analysis
Continuous variables were compared using the Mann–Whitney U test and the Student t-
test, as appropriate. Qualitative variables were compared using the chi-square test. Odds
ratios (ORs) and 95% confidence intervals (CIs) were calculated, and a p-value of <0.05 was
considered statistically significant. Multivariate conditional logistic-regression analysis of
factors potentially associated with mortality was done that included all statistically signifi-
cant variables in the univariate analysis, together with sex, age, and all clinically important
variables, regardless of whether they were statistically significant. Kaplan–Meier curves
were drawn to show the rate of survival in the PBSI and MBSI groups. The analysis was per-
formed by stepwise logistic regression in SPSS version 17.0 (SPSS Institute Inc., Chicago, IL,
USA).
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Results
Patient characteristics
Of the 1896 episodes of BSI, we identified 194 (10.2%) episodes of PBSI in 179 patients and
1702 (89.8%) episodes of MBSI in 1155 patients. The baseline characteristics and clinical mani-
festations of patients with PBSI and MBSI are summarised in Table 1. Patients with PBSI were
more likely to present with neutropenia and to have a biliary stenting in place. In addition,
there was a trend towards the use of corticosteroids in this group of patients. The most fre-
quent sources of BSI were endogenous (22.2%), catheter-related infection (19.8%) and urinary
tract infection (10.6%). Cholangitis, neutropenic enterocolitis, abdominal infection and peri-
rectal infection were more frequent in patients with PBSI, whereas urinary tract, respiratory
tract and catheter infections were more common in patients with MBSI.
Risk factors for PBSI
Table 2 summarises the risk factors for PBSI by univariate and multivariate analysis. After
adjustment, biliary stenting (OR 2.92; 95% CI, 1.52–5.61), neutropenia (OR 2.2; 95% CI, 1.44–
3.35), corticosteroid therapy (OR 1.48; 95% CI, 1.08–2.03), cholangitis (OR 2.17; 95% CI 1.11–
4.24) and abdominal infections (OR 2.48; 95% CI, 1.41–4.34) were identified as independent
risk factors for PBSI. By contrast, urinary tract (OR 0.33; 95% CI, 0.13–0.85) and respiratory
tract (OR 0.25; 95% CI, 0.09–0.71) infections were identified as low risk factors for PBSI.
Aetiology and antimicrobial resistance
Table 3 shows the aetiology of all episodes of BSI compared by groups. A total of 419 microor-
ganisms were isolated in 194 episodes of PBSI. Among these, 27 episodes had 3 organisms and
2 episodes had 4 organisms. The most frequent combinations were Gram-positive plus Gram-
negative organisms (36.1%) or Gram-negative plus Gram-negative organisms (30.4%).
Overall, Gram-negative organisms were the leading cause of BSI in both the PBSI and
MBSI groups, with Escherichia coli and Pseudomonas aeruginosa being the most frequent caus-
ative agents. Enterococcus spp. were the most frequent Gram-positive organisms isolated in the
cases of PBSI, followed by viridans group streptococci. In patients with MBSI, coagulase-nega-
tive staphylococci (CNS) were the most common Gram-positive agents, followed by Enterococ-
cus spp. and Staphylococcus aureus. Among the anaerobes, clostridial infections were more
common in polymicrobial episodes, whereas Bacteroides spp. were more frequently found in
MBSI. Overall, infection due to MDR organisms was observed in 13.6% of cases, and it was
more frequently found in episodes of PBSI (20.6% vs 12.9%; p = 0.003).
Considering only the polymicrobial episodes, patients with solid tumours presented more
frequently with infection due to ESBL-producing Enterobacteriaceae compared to patients
with haematological malignancies (11.5% vs 1.7%; p = 0.008).
Antibiotic treatment and outcomes
Initial empirical antibiotic treatment and patients’ outcomes are detailed in Table 4. Patients
with PBSI more frequently received carbapenems and a combination therapy for empirical
antibiotic therapy than patients with MBSI. Among patients with PBSI, 54 were considered to
have received inadequate initial empirical antibiotic therapy. Reasons for inappropriateness
were as follows: 18 patients with E. faecium BSI received a β-lactam, 13 patients had MDR
organisms, 10 patients did not receive any empirical treatment, 3 patients with fungal infection
did not receive antifungals, and 3 patients with CNS infection were given cefepime and
Polymicrobial bloodstream infection in patients with cancer
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N = 1702 (%)
P value
Age (years, median, range) 61 (14–90) 60 (21–84) 0.71
Male sex 122 (62.9) 1039 (61) 0.618
Haematological malignancy 116 (59.8) 1012 (59.5) 0.939
Haematopoietic stem cell transplant (HSCT) 26 (13.5) 288 (16.9) 0.261
Chronic advanced cancer 68 (39.3) 563 (38.7) 0.881
Other comorbidities 81 (41.8) 609 (35.8) 0.101
MASCC score < 21 45 (45.6) 291 (38.3) 0.173
Neutropenia (<500 n/μL) 104 (53.6) 766 (45) 0.023
Community acquired 16 (8.2) 179 (10.5) 0.324
Previous antibiotics (1 month) 96 (50) 822 (48.4) 0.682
Previous chemotherapy (1 month) 145 (74.7) 1195 (70.3) 0.193
Previous corticosteroid therapy (1 month) 83 (42.8) 609 (35.8) 0.056
Previous hospital admission (3mo) 100 (52.1) 842 (49.7) 0.527
Biliary stenting 31 (16) 82 (4.8) <0.001
Other previous manipulations 18 (9.3) 146 (8.6) 0.746
Source of BSI
Cholangitis 39 (20.1) 149 (8.8) <0.001
Other abdominal site infections. 26 (13.4) 138 (8.1) 0.013
Neutropenic enterocolitis 11 (5.7) 45 (2.6) 0.018
Perirectal infection 7 (3.6) 15 (0.9) 0.005
Urinary tract 5 (2.6) 197 (11.6) <0.001
Respiratory tract 4 (2.1) 165 (9.7) <0.001
Endogenous source 52 (26.8) 369 (21.7) 0.104
Catheter related 28 (14.4) 349 (20.5) 0.045
Mucositis 3 (1.5) 58 (3.4) 0.2
Skin and soft tissue 2 (1) 50 (2.9) 0.162
Unknown 14 (7.2) 131 (7.7) 0.811
Fever38˚C 164 (84.5) 1426 (84.4) 0.969
https://doi.org/10.1371/journal.pone.0185768.t001
Table 2. Risk factors for polymicrobial bloodstream infection by univariate and multivariate analysis.
Characteristics PBSI
n = 194 (%)
MBSI
n = 1702 (%)
p-Value Adjusted OR (95% CI) p-Value
Sex (male) 122 (62.9) 1039 (61) 0.618 1 (.66–1.25) 0.825
Age (years, median, range) 61 (14–90) 60 (21–84) 0.71 1 (.99–1.02) 0.564
Biliary stenting 31 (16) 82 (4.8) <.001 2.92 (1.52–5.61) 0.001
Neutropenia (<500/mm3) 104 (53.6) 766 (45) 0.023 2.2 (1.44–3.35) 0.001
Corticosteroid therapy 83 (42.8) 609 (35.8) 0.056 1.48 (1.08–2.03) 0.014
Cholangitis 39 (20.1) 149 (8.8) <0.001 2.17 (1.11–4.24) 0.023
Other abdominal site 26 (13.4) 138 (8.1) 0.013 2.48 (1.41–4.34) 0.002
Neutropenic enterocolitis 11 (5.7) 45 (2.6) 0.018 1.88 (.93–3.82) 0.08
Perirectal infection 7 (3.6) 15 (.9) 0.005 3.87 (1.52–9.90) 0.005
Urinary tract 5 (2.6) 198 (11.6) <.001 .33(.13-.85) 0.022
Respiratory tract 4 (2.1) 163 (9.6) <.001 .25(.09-.71) 0.009
Catheter related 28 (14.4) 349 (20.5) 0.0431 .83(.52–1.32) 0.431
https://doi.org/10.1371/journal.pone.0185768.t002
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N = 1702 (%)
Gram-negative 219 (52.52) 872 (51.23)
Escherichia coli 74 (33.79) 421 (48.28)
Pseudomonas aeruginosa 43 (19.63) 124 (14.22)
Klebsiella pneumoniae 38 (17.35) 129 (14.79)
Klebsiella oxytoca 10 (4.57) 11 (1.26)
Enterobacter spp. 18 (8.22) 66 (7.57)
Citrobacter spp. 6 (2.74) 7 (0.8)
Morganella morganii 5 (2.28) 2 (0.23)
Proteus spp. 5 (2.28) 15 (1.72)
Acinetobacter spp. 3 (1.37) 6 (0.69)
Salmonella enterica serovar enteritidis 0 15 (1.72)
Stenotrophomonas maltophilia 1(0.46) 21 (2.41)
Other 16 (7.31) 55 (6.31)
Gram-positive 173 (41.29) 735 (43.18)
Staphylococcus aureus 15 (8.67) 115 (15.65)
Methicillin-resistant S. aureus 3 (1.73) 21 (2.86)
Coagulase-negative staphylococci 40 (23.12) 217 (29.52)
Viridans group streptococci 51 (29.48) 64 (8.71)
Streptococcus gallolyticus 6 (3.47) 17 (2.31)
Streptococcus agalactiae 2(1.16) 13(1.77)
Streptococcus pneumoniae 3 (1.73) 103(14.01)
Enterococcus spp. 53 (30.64) 130 (17.68)
Enterococcus faecium 25 (14.45) 78(10.61)
Enterococcus faecalis 18 (10.40) 44 (5.99)
Other Enterococcus spp. 10 (5.78) 8(1.09)
Listeria monocytogenes 1 (0.58) 25(3.40)
Other 2 (1.16) 30(4.08)
Anaerobes 21 (5.04) 62 (3.64)
Clostridium spp. 10 (50) 15 (24.19)
Bacteroides spp. 5 (23.8) 28 (45.16)
Bacteroides fragilis 2 (10) 21 (33.87)
Other 6 (30) 18 (29.03)
Fungi 6 (1.44) 33 (1.94)
Candida albicans 5 (83.3) 31 (93.94)
Scedosporiumspp. 1 (16.67) 0
Fusarium solanii 0 2 (6.06)
Antibiotic Resistant
Multidrug-resistant (MDR) 40 (20.6) 219 (12.9)
Ampicillin-resistant vancomycin-susceptible E. faecium 22 (11.3) 68 (4)
ESBL-producing Enterobacteriaceae 11 (5.7) 75 (4.4)
AmpC-producing Enterobacteriaceae 4 (2.1) 19 (1.1)
MDR-Pseudomonas aeruginosa 1 (0.5) 12 (0.7)
Vancomycin-resistant Enterococcus spp. 6 (3.1) 3 (0.2)
https://doi.org/10.1371/journal.pone.0185768.t003
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amikacin. The remaining 17 patients with PBSI received an antibiotic active against only one
of the infective organisms.
Patients with PBSI presented poorer outcomes with higher early and overall case-fatality
rates than patients with MBSI. The Kaplan–Meier curves showing the rate of survival in the
PBSI and MBSI groups are detailed in Fig 1. Among patients with PBSI, solid tumours were
associated with a higher overall case-fatality rate than were haematological malignancies
(39.7% vs 31%; p = 0.057), but there were no differences in early case-fatality rates (15.4% vs
14.8%; p = 0.909).
Risk factors for overall case-fatality rate
Risk factors for the overall case-fatality rate are detailed in Table 5. After applying a logistic-
regression model, the only variables found to be independent risk factors for overall case-fatal-
ity were a high-risk MASCC (Multinational Association of Supportive Care in Cancer) index
score (OR 0.28; 95% CI, 0.17–0.46), corticosteroid therapy (OR 1.72; 95% CI, 1.1–2.7), persis-
tent bacteraemia (OR 3.4; 95% CI, 1.82–6.33) and septic shock (OR 2.65; 95% CI, 1.51–4.66).
PBSI was not a risk factor for overall mortality.
Discussion
In this prospective study of a large cohort of patients with cancer, PBSI occurred in one out of
ten patients. Multidrug resistance was frequent in those with PBSI, and outcomes were poorer,
particularly in those with corticosteroid therapy, with a high-risk MASCC index score, and
presenting with septic shock or persistent bacteraemia. The incidence of PBSI in the general
population ranges from 6% to 14%; but it seems to increase in patients with cancer, reaching
up to 32% in high-risk patients with leukaemia and in recipients of autologous haematopoietic
stem cell transplants [8, 10– 12, 20, 21]. Although our results seem to be in line with these






Empirical antibiotic treatment 184 (94.8) 1595 (93.5) 0.640
Combination therapy* 95 (51.6) 713 (44.7) 0.074
Monotherapy 89 (48.4) 882 (55.3) 0.074
β-lactam + β-lactamase inhibitor 44 (49.4) 405 (45.9) 0.526
Carbapenem 24 (27) 185 (21) 0.19
Cephalosporine 10 (11.2) 155 (17.6) 0.128
Aztreonam 1 (1.1) 11 (1.2) 1
Quinolone 3 (3.4) 56 (6.4) 0.261
Aminoglycoside 1 (1.1) 7 (0.8) 0.743
Glycopeptide 8 (9) 97 (11) 0.561
Inadequate empirical antibiotic therapy 54 (25.7) 438 (27.8) 0.527
Septic shock at presentation 24 (12.4) 191 (11.2) 0.64
Intensive care unit admission 19 (9.8) 126 (7.4) 0.24
Invasive mechanical ventilation 13 (6.7) 67 (4) 0.07
Early case-fatality rate (7d) 29 (15) 176 (10.4) 0.04
Overall case-fatality rate (30d) 62 (32) 349 (20.9) <0.001
*More than 80% of the patients who received a combination therapy were treated with a β-lactam (mainly a cephalosporin or a carbapenem) plus an
aminoglycoside.
https://doi.org/10.1371/journal.pone.0185768.t004
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studies, it is difficult to assess the real incidence of PBSI over time because of the heterogeneity
of the population studied and the lack of consistent definitions used [14].
We found that PBSI was more frequent in patients with perirectal infections, neutropenic
enterocolitis or cholangitis, especially if they had a biliary prosthesis. As we have previously
Fig 1. Kaplan–Meier survival curves of patients with polymicrobial bloodstream infection and
monomicrobial bloodstream infection.
https://doi.org/10.1371/journal.pone.0185768.g001
Table 5. Risk factors for overall case-fatality rate by univariate and multivariate analysis.
Characteristics Survived
n = 132 (%)
Died
n = 62 (%)
p-Value Adjusted OR (95% CI) p-Value
Sex (male) 82 (62.1) 40 (64.5) 0.957 1.51 (.965–2.38) 0.071
Age (years, median, range) 60 (14–89) 63 (21–90) <0.001 0.101 (.99–1.03) 0.148
Solid tumor 48 (36.4) 31 (50) 0.071 1.44 (.79–2.61) 0.226
MASCC risk score< 21* 26 (34.7) 19 (79.2) <0.001 0.283 (.17-.46) <0.001
Corticosteroid therapy 49 (37.1) 34 (54.8) 0.020 1.72 (1.1–2.7) 0.019
Persistent bacteremia 13 (10.2) 10 (23.3) 0.029 3.4 (1.82–6.33) <0.001
Respiratory source 0 4 (6.5) 0.010 1.16 (0.48–2.79) 0.74
Septic Shock 11 (8.3) 13 (21) 0.013 2.65 (1.514–4.66) 0.001
Inadequate empirical antibiotic therapy 98 (74.2) 40 (65.5) 0.215
Malignancy-related complications 27 (20.5) 25 (40.3) 0.004 1.87 (.52–6.74) 0.34
Multidrug-resistant bacteria 27 (20.5) 13 (21) 0.934
*MASCC: Multinational Association for Supportive Care in Cancer
https://doi.org/10.1371/journal.pone.0185768.t005
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described, cholangitis is a frequent cause of PBSI in patients with solid tumours, and obstruc-
tion of the prosthesis may play a role in the pathogenesis of infection [22]. The abdomen was
the most frequent source of PBSI, presumably because the site of entry of the infection is often
the site of the primary tumour, and because of the high incidence of gastrointestinal ulcera-
tions in patients with leukaemia [9, 13, 23].
As documented by other investigators, Gram-negative organisms were the most frequent
causative agents in our study. Remarkably, enterococci were the most frequent Gram-positive
pathogens in patients with PBSI. Compared to previous studies, in which streptococcal BSI
was the predominant Gram-positive infection [13, 15], our data show that enterococci may be
taking over from other Gram-positives. An interesting finding that has not previously been
documented was the incidence of multidrug resistance, which reached 20% in our study. The
most frequent MDR organisms were ampicillin-resistant vancomycin-susceptible E. faecium,
followed by ESBL-producing Enterobacteriaceae. Infections caused by ampicillin-resistant E.
faecium are increasing in patients with cancer, but their impacton outcomes seem to be less
relevant than infections due to vancomycin-resistant strains [24, 25]. Moreover, there is still
controversy regarding the association between E. faecium infection and mortality [24, 26, 27].
Likewise, infections due to ESBL-Enterobacteriaceae are also increasing in patients with cancer
[28–32].
The emergence of multidrug resistance in patients with cancer is of special concern because
inadequate initial empirical antibiotic therapy may negatively influence outcomes [30–31]. In
this regard, we found that inadequate initial empirical antibiotic therapy was not associated
with higher case-fatality rates. Nevertheless, it should be noted that infections in patients
receiving inadequate therapy were mainly caused by E. faecium and CNS, which are intrinsi-
cally resistant to the most frequently used empirical antibiotic therapy in our institution (cefe-
pime plus amikacin). As previously stated, it seems that ampicillin-resistant vancomycin-
susceptible E. faecium BSI may not be clearly associated with poor outcomes. Moreover, BSI
due to CNS has previously been identified as a predictor of lower mortality in neutropenic
patients with haematological malignancies, as mentioned in other studies [7, 33,34].
We found lower case-fatality rates compared with other studies of PBSI involving immuno-
competent and immunosuppressed cancer patients [8, 10, 11, 13]. However, it should be noted
that most of the existing studies were performed several decades ago, and that the management
of patients with PBSI has improved over the intervening period. Nevertheless, we found that a
high-risk MASCC index score, corticosteroid therapy, persistent bacteraemia and septic shock
were associated with higher mortality. The MASCC score is frequently used as a predictor of
complications in patients with febrile neutropenia, with lower scores indicating a higher risk
of developing severe complications and death[35]. Likewise, septic shock at presentation and
the persistence of bacteraemia are clinical features associated with severe sepsis and/or uncon-
trolled sepsis [33]. Corticosteroid therapy to mitigate symptomatology has previously been
identified as a risk factor for mortality in our cohort, mainly in those with advanced underly-
ing malignancy [6, 24].This may be related to the fact that corticosteroids decrease the immune
response and favour severe sepsis [36].
This study has some limitations that should be acknowledged. First, this is a single-centre
study in a particular geographical area, so caution should be exercised when extrapolating the
data to other settings. Second, as with any observational study, there is a potential for residual
confounding; however, the strengths of the current study include the prospective collection of
data, the large number of bacteraemia episodes in patients with cancer and the use of a uni-
form and comprehensive protocol for data collection.
In conclusion, PBSI is especially frequent in patients with cancer who have cholangitis, biliary
stenting, or neutropenic enterocolitis. Enterococcal BSI is gaining increasing epidemiological
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importance, as is the emergence of multidrug resistance. Physicians should be able to identify
patients at risk of PBSI and provide an initial empirical antibiotic regimen that covers the most
frequent pathogens involved in this serious infection.
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